Compare CLMT & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | SRRK |
|---|---|---|
| Founded | 1916 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.2B |
| IPO Year | 2024 | 2018 |
| Metric | CLMT | SRRK |
|---|---|---|
| Price | $36.58 | $43.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 18 |
| Target Price | $55.80 | ★ $70.44 |
| AVG Volume (30 Days) | 1.6M | ★ 1.6M |
| Earning Date | 11-06-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,137,100,000.00 | N/A |
| Revenue This Year | $30.93 | N/A |
| Revenue Next Year | N/A | $2,600.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.85 | $34.25 |
| 52 Week High | $59.87 | $61.76 |
| Indicator | CLMT | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 25.23 | 47.19 |
| Support Level | $30.74 | $38.72 |
| Resistance Level | $37.44 | $48.27 |
| Average True Range (ATR) | 2.89 | 2.40 |
| MACD | -1.39 | 0.54 |
| Stochastic Oscillator | 14.45 | 27.88 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.